Literature DB >> 30482135

Haemodynamic effects of cold versus warm fluid bolus in healthy volunteers: a randomised crossover trial.

Olof Wall1, Lars Ehrenberg2, Eva Joelsson-Alm3, Johan Mårtensson4, Rinaldo Bellomo5, Christer Svensén3, Maria Cronhjort3.   

Abstract

OBJECTIVE: To test the hypothesis that changes in cardiac index and mean arterial pressure (MAP) during and after a fluid bolus (FB) are altered by fluid temperature.
DESIGN: Randomised, controlled, crossover trial.
SETTING: Research laboratory at Swedish teaching hospital. PARTICIPANTS: Twenty-one healthy adult volunteers.
INTERVENTIONS: Subjects were randomly allocated to 500 mL of Ringer's acetate at room temperature (22°C; cold) or body temperature (38°C; warm). MAIN OUTCOME MEASURES: For 2 hours after starting the FB, we measured cardiac index, MAP, systolic blood pressure, diastolic blood pressure and pulse rate (PR) continuously. We recorded temperature and O2 saturation every 5 minutes during infusion and every 15 minutes thereafter. In a second session, volunteers crossed over.
RESULTS: During the first 15 minutes, mean cardiac index increased more with warm FB (0.09 L/min/m2 [95% CI, 0.06-0.11] v 0.03 L/min/m2 [95% CI, 0.01-0.06]; P < 0.001). This effect was mediated by a significant difference in mean PR (+0.80 beats/min [95% CI, 0.47-1.13] v -1.33 beats/ min [95% CI, -1.66 to -1.01]; P < 0.010). In contrast, MAP increased more with cold FB (4.02 mmHg [95% CI, 3.63-4.41] v 0.60 mmHg [95% CI, 0.26-0.95]; P < 0.001). Cardiac index and MAP returned to baseline after a median of 45.3 min (interquartile range [IQR], 10.7-60.7 min) and 27.7 min (IQR, 5.3-105.0 min), respectively, after cold FB, and by 15.8 min (IQR, 3.8-64.3 min) and 22.7 min (IQR, 3.3-105.0 min), respectively, after warm FB.
CONCLUSION: Intravenous FB at body temperature leads to a greater increase in cardiac index compared with room temperature, while the reverse applies to MAP. These findings imply that in healthy volunteers, when a room temperature FB is given, the temperature of the fluid rather than its volume accounts for most of the MAP increase. TRIAL REGISTRATION: EudraCT no. 2016-002548-18 and Clinicaltrials.gov NCT03209271.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30482135

Source DB:  PubMed          Journal:  Crit Care Resusc        ISSN: 1441-2772            Impact factor:   2.159


  1 in total

1.  Circulatory Response to Rapid Volume Expansion and Cardiorespiratory Fitness in Fontan Circulation.

Authors:  Thomas Möller; Vibeke Klungerbo; Simone Diab; Henrik Holmstrøm; Elisabeth Edvardsen; Guro Grindheim; Henrik Brun; Erik Thaulow; Alvaro Köhn-Luque; Assami Rösner; Gaute Døhlen
Journal:  Pediatr Cardiol       Date:  2021-12-17       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.